Caplin Point Laboratories Limited (NSE:CAPLIPOINT)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharmaceutical Formulations	21.87B	19.40B	16.96B	14.68B	12.71B
Pharmaceutical Formulations Growth	12.77%	14.35%	15.51%	15.53%	19.64%
Total	21.87B	19.40B	16.96B	14.68B	12.71B
Total Growth	12.77%	14.35%	15.51%	15.53%	19.64%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Rest of The World	17.34B	15.83B	13.81B	-	-
Rest of The World Growth	9.53%	14.65%	-	-	-
United States of America (USA)	4.53B	3.55B	3.13B	-	1.27B
United States of America (USA) Growth	27.89%	13.13%	-	-	-
Unallocated	-	964.30M	669.40M	-	-
Unallocated Growth	-	44.05%	-	-	-
Latin America	-	-	-	-	11.04B
Africa	-	-	-	-	380.82M
Total	21.87B	20.34B	17.61B	-	12.69B
Total Growth	7.54%	15.49%	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 25, 2026

Data Sources Report a data error